O12. Survival of patients with advanced EGFR-mutated NSCLC treated with EGFR TKIS in routine clinical practice

BACKGROUND: The use of epidermal growth factor receptor (EGFR) TKIs in EGFR-mutated non-small cell lung cancer (NSCLC) moved the survival boundary for these patients up to impressive 19 to 35 months, as reported in seven randomized clinical trials (RCTs). In addition, latest results of RCTs show sig...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Transl Lung Cancer Res
Asıl Yazarlar: Hitij, Nina Turnsek, Sadikov, Aleksander, Knez, Lea, Mohorcic, Katja, Jakelj, Andraz, Cufer, Tanja
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Pioneer Bioscience Publishing Company 2014
Konular:
CELCC 2014 Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367788/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB011
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller